TSE:MFC

Manulife Financial (MFC.TO)

60.67
+0.26 (0.43%)
as of Jul 22, 2026, 8:00:00 pm Market Open.
1632 watching
0
Investor Insights
star iconJul 22, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has garnered a mostly positive outlook among various experts, highlighting its competitive positioning within the Canadian financial sector, particularly in comparison to major banks like TD and SLF. Analysts note MFC's ongoing strength in wealth management and healthy growth prospects in Asia, although there are concerns regarding its current valuation, as it trades over 2x book value and exhibits only moderate earnings growth. Despite being classified as slightly overbought, its charts remain healthy, with many recommending caution yet seeing potential for growth in the long run. The company's strong dividend yield and management strategies, particularly in alternative investments, also contribute to a favorable long-term investment story, although short-term volatility may present opportunities for those willing to enter at lower price points.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
SLF,SLF
BUY
Has disappointed a lot of people for a while. The valuation is silly, trading at 6x whereas Sunlife is at 10x. There is still tail risk with variable annuities. Operationally, they are doing well with good growth in Asia. 9-10% EPS growth trading at 6.6x. Comfortable owning it. Thinks it will work at these levels.
COMMENT
They have grown a franchise in Asia, and there's more upside there in life insurance whereas North America is saturated. MFC has had historic issues in investing, which has kept him away. The accounting can be complex in this business. He owns no lifecos.
HOLD
It has been a weaker performer and it comes down to the John Hancock division in the US. In the next 12-18 months they should work through this. He'd prefer BNS-T for yield.
PARTIAL SELL
Insurance companies have been quite sleepy this year. SLF stock's been flat since 2019. Not a ton of dividend growth. Good positive exposure to rising rates longer term. Well managed. MFC has more catalysts, cheaper, higher dividend yield. Trimmed weighting to insurance broadly and moved into utilities, renewables, and infrastructure.
BUY
It is almost ridiculously cheap. Operating earnings are growing. They have growth in Asia. They are a cheap stock with a decent dividend.
PAST TOP PICK
(A Top Pick Oct 08/20, Up 29%) Pretty washed out name last year, but low hanging fruit. Tripped up with higher rates, as it affected their hedge book. 15% growth with a 7 PE, decent dividend, growth in Asia, wealth management. Hold your nose and buy it. It will help your portfolio over time.
BUY
It corrected more than other financials in yesterday's rout. Their growth has been in China, so maybe they're getting hit by the Evergrande implosion. MFC has always reacted with more volatility than other financial stocks, like cutting their dividend in 2008. At $23.75, it's a good buy. In coming years, he expects them to continue to do well. Prudential sold off some of its businesses, so this adds a little to MFC's underlying value, more than people give it credit for. Very good managers. He'd definitely recommend it.
TOP PICK
He likes their Asian growth, which will be a high-growth sector in terms of insurance and wealth management. Dividend growth has been impressive for years. He's been adding to this for a long time. He likes MFC vs. the banks, both dividend plays, though he's lessened his bank exposure a little. (Analysts’ price target is $29.65)
DON'T BUY

Fundamentals are strong, but not reflected in the stock price MFC chooses to invest most of its cash to growing its Asian business. He sold his holdings around the 2008 crash and bought SunLife instead, because they were too risky among the insurers, then MFC de-risked too much after the 2008-9 recession. If interest rates rise, he'd rather be in SunLife or Great-west Life. MFC volumes are high, because it is the biggest lifeco in Canada. He prefers SunLife.

DON'T BUY
Don't own any of the insurance companies. There are other things that are better. Portfolio yield has come down over the last year. Many companies are now buying back stocks rather than paying dividends.
BUY
Excellent dividend and cheap in terms of value. But it begs his imagination that with all that's going for it why the stock hasn't moved higher. Buy and hold on. Great dividend of 4.4%.
TOP PICK
A blue chip Canadian name. Not his historic preferred name in insurance but it has turned a corner with some innovation investments. Simplifying how things are done. Some nice exposure to NA and the developing world. Shaping up very well, shifting down to 50 and 200 day moving average. (Analysts’ price target is $29.65)
BUY
Likes it, continues to buy. Geographically well diversified. Q2 earnings last week look tepid on the surface. Earnings grew 6% Y/Y. Grew organically 17%, and this is respectable. Global wealth and asset management grew 50%. A secular grower. Undemanding valuation. Trades at 7.5x earnings. Good combination of quality, growth, value. Yield of about 4.5%.
DON'T BUY
Why doesn't this trade above $30 given all its positive metrics and recent strong report? Yes, it trades cheaply at 1x book, lower then the Canadian banks. The problem is that the operations of Canadian insurers are complicated during very low interest rates. Insurers invest a lot of their money in low-duration, fixed-income assets--namely bonds--and those aren't paying much at all. The risk is that if inflation rises, then those assets will be hit as the insurers pay out policy holders more money. Also, there's worry over MFC's expansion into Asia, despite strong recent numbers, as the John Hancock expansion of some years ago remains fresh in minds.
TOP PICK
One of largest lifecos in the world. Asia counts for 35% of revenue, with greater demand in the future. Growing middle class and aging demographic are a bonus. At 1x price to book, trades at a discount to the peer group. Interest rates will benefit. Yield is 4.59%. (Analysts’ price target is $29.22)
Showing 226 to 240 of 2,283 entries